Market open
Fortress Biotech/$FBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fortress Biotech
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
Ticker
$FBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
101
ISIN
US34960Q3074
Website
Fortress Biotech Metrics
BasicAdvanced
$53M
-
-$2.69
1.83
-
Price and volume
Market cap
$53M
Beta
1.83
52-week high
$2.89
52-week low
$1.33
Average daily volume
169K
Financial strength
Current ratio
1.266
Quick ratio
0.948
Long term debt to equity
-4,422.871
Total debt to equity
-4,620.438
Interest coverage (TTM)
-7.61%
Management effectiveness
Return on assets (TTM)
-41.30%
Return on equity (TTM)
424,052.63%
Valuation
Price to revenue (TTM)
0.641
Price to book
2.19
Price to tangible book (TTM)
-5.44
Price to free cash flow (TTM)
-0.373
Growth
Revenue change (TTM)
-31.76%
Earnings per share change (TTM)
-68.24%
3-year revenue growth (CAGR)
-5.71%
3-year earnings per share growth (CAGR)
-39.06%
What the Analysts think about Fortress Biotech
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Fortress Biotech stock.
Fortress Biotech Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Fortress Biotech Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Fortress Biotech News
AllArticlesVideos
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewsWire·21 hours ago
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates
GlobeNewsWire·3 days ago
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Fortress Biotech stock?
Fortress Biotech (FBIO) has a market cap of $53M as of May 16, 2025.
What is the P/E ratio for Fortress Biotech stock?
The price to earnings (P/E) ratio for Fortress Biotech (FBIO) stock is 0 as of May 16, 2025.
Does Fortress Biotech stock pay dividends?
No, Fortress Biotech (FBIO) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Fortress Biotech dividend payment date?
Fortress Biotech (FBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Fortress Biotech?
Fortress Biotech (FBIO) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.